You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)擬配售1.3億股籌資34.77億港元 用於增強研發能力及豐富產品管線
格隆匯 04-22 07:57

格隆匯4月22日丨翰森製藥(03692.HK)公佈,於2020年4月22日,公司與配售代理訂立配售協議,公司擬以配售價每股配售股份26.75港元配售1.3億股,佔公司已發行股份總數約2.25%及配售事項後經擴大已發行股份總數約2.20%。

配售事項所得款項總額預期約34.88億港元,所得款項淨額則約34.77億港元。

公司表示,集團主要於中國從事一系列藥品的研發、生產及銷售活動。公司計劃將配售事項所得款項淨額用於研發(包括但不限於公司現有及未來的國內及海外藥品研發)項目、擴充公司的研發團隊及於技術的投資,以進一步增強公司的研發能力及豐富公司的產品管線。董事認為配售事項屬公司為集團業務發展籌集資金並豐富公司股東基礎的契機。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account